EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieVergleichsstudieOpen Access

Adjuvant Nivolumab vs Observation in Resected Non–Small Cell Lung Cancer

Jamie E Chaft, Zhuoxin Sun, Charles M Rudin, Onkar V Khullar, Charles B Simone, Kurt Oettel, David Kozono, Rajitha Sunkara, Bryan Faller, James M Isbell, Vladimir Hugec, Asheesh Shipstone und 17 weitere

JAMA · 11.08.2026 · 336 (6) · 464

DOI: 10.1001/jama.2026.8992 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA, erschienen am 11.08.2026. Verfasst von Jamie E Chaft und 28 weiteren Autor:innen. Beteiligte Einrichtung: Memorial Sloan Kettering Cancer Center New York, New York. Hauptthemen laut MEDLINE: Antineoplastic Agents, Immunological, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Nivolumab. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Preoperative and perioperative nivolumab improve event-free survival in resectable non–small cell lung cancer. The role of adjuvant nivolumab after upfront surgery is unknown.

Objective

To determine whether adjuvant nivolumab improves disease-free survival and overall survival in patients with resected non–small cell lung cancer with any tumor programmed death-ligand 1 (PD-L1) expression and in those with at least 50% PD-L1 expression. Design, Setting, and Participants This open-label, randomized phase 3 study enrolled participants from May 2016 through September 2019, with median follow-up of 72.6 months at the data cutoff in December 2025. The study was conducted at 378 centers in the US National Clinical Trials Network. Patients were identified through a screening trial. Those with resected tumors at least 4 cm and/or who were lymph node positive (N1/N2) were eligible for inclusion after completion of planned standard adjuvant therapy if the tumor was adenocarcinoma without sensitizing sequence variants in EGFR and ALK or squamous cell carcinoma.

Intervention

Patients were randomized in a 1:1 ratio to receive nivolumab 480 mg intravenously every 4 weeks for up to 1 year or standard care observation. Main Outcomes and Measures Co–primary end points were disease-free survival in the intention-to-treat population and in those with tumoral PD-L1 expression at least 50%. Overall survival was examined if the corresponding test of disease-free survival was statistically significant.

Results

A total of 466 patients (median age, 66 years; 241 [52%] male) were assigned to receive nivolumab and 469 (median age, 67 years; 245 [52%] male) to undergo standard care observation. The median duration of follow-up was 72.6 months. The trial was stopped for futility at 78% information. In the intention-to-treat population, median disease-free survival was 71.3 months with nivolumab and 68.8 months with observation (hazard ratio for progression or death, 0.97 [97% CI, 0.79-1.20]; [95% CI, 0.81-1.17]; 1-sided P = .39). In the subset of participants with PD-L1 of at least 50%, median disease-free survival was 89.8 months with nivolumab and 78.5 months with observation (hazard ratio for progression or death, 0.86 [98% CI, 0.55-1.34]; [95% CI, 0.59-1.25]; 1-sided P = .22). Conclusions and Relevance Adjuvant nivolumab was not associated with improved disease-free survival in patients with resected non–small cell lung cancer without sensitizing EGFR and ALK alterations when given after planned adjuvant chemotherapy and/or radiotherapy. Trial Registration Clinicaltrials.gov Identifier: NCT02595944

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Agents, ImmunologicalCarcinoma, Non-Small-Cell LungLung NeoplasmsNivolumabWatchful WaitingAgedFemaleHumansMaleMiddle AgedB7-H1 AntigenChemotherapy, AdjuvantDisease-Free SurvivalPneumonectomyProgrammed Cell Death 1 ReceptorFollow-Up StudiesChemoradiotherapy, AdjuvantAdultAged, 80 and over

Substanzen

Antineoplastic Agents, ImmunologicalB7-H1 AntigenCD274 protein, humanNivolumabProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Memorial Sloan Kettering Cancer Center New York, New York.
  • Weill Cornell Medical College, New York, New York.
  • Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
  • Emory University, Winship Cancer Institute, Atlanta, Georgia.
  • Gundersen Lutheran Medical Center, La Crosse, Wisconsin.

Förderung

  • NCI NIH HHS

Zitieren

APA

Chaft, J. E., Sun, Z., Rudin, C. M., Khullar, O. V., Simone, C. B., Oettel, K., Kozono, D., Sunkara, R., Faller, B., Isbell, J. M., Hugec, V., Shipstone, A., McGary, E. C., Clarke, J. M., Talsania, A., Ding, L., Govindan, R., Sands, J. M., Heymach, J. V., …, & Ramalingam, S. S. (2026). Adjuvant Nivolumab vs Observation in Resected Non–Small Cell Lung Cancer. JAMA, 336(6), 464. https://doi.org/10.1001/jama.2026.8992

Vancouver

Chaft JE, Sun Z, Rudin CM, Khullar OV, Simone CB, Oettel K, et al. Adjuvant Nivolumab vs Observation in Resected Non–Small Cell Lung Cancer. JAMA. 2026;336(6):464. doi:10.1001/jama.2026.8992

BibTeX
@article{Chaft2026,
  author = {Chaft, Jamie E and Sun, Zhuoxin and Rudin, Charles M and Khullar, Onkar V and Simone, Charles B and Oettel, Kurt and Kozono, David and Sunkara, Rajitha and Faller, Bryan and Isbell, James M and Hugec, Vladimir and Shipstone, Asheesh and McGary, Eric C and Clarke, Jeffrey M and Talsania, Ashita and Ding, Li and Govindan, Ramaswamy and Sands, Jacob M and Heymach, John V and Raez, Luis E and Malik, Shakun M and Stinchcombe, Thomas E and Mandrekar, Sumithra J and Bradley, Jeffrey and Gerber, David E and Vokes, Everett and Gandara, David and Staley, Charles and Ramalingam, Suresh S},
  title = {Adjuvant Nivolumab vs Observation in Resected Non–Small Cell Lung Cancer},
  journal = {JAMA},
  year = {2026},
  volume = {336},
  number = {6},
  pages = {464},
  doi = {10.1001/jama.2026.8992}
}
Kostenlos starten →